ASH 2019 | GRIFFIN update: depth of response to D-RVd in transplant eligible NDMM
Peter Voorhees
• 8 Dec 2019
Peter Voorhees, MD, Levine Cancer Institute, Atrium Health, Charlotte, NC, gives an update on the GRIFFIN study (NCT02874742). This phase 2 randomized trial evaluated daratumumab plus lenalidomide, bortezomib and dexamethasone (RVd) in autologous stem cell transplant eligible newly diagnosed multiple myeloma (NDMM) patients. The data demonstrated that adding daratumumab to RVd significantly improved response rates and depth of response, including stringent complete response and MRD negativity. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
